It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inhibition of the eukaryotic initiation factor 5A activation by the spermidine analogue GC7 has been shown to protect proximal cells and whole kidneys against an acute episode of ischaemia. The highlighted mechanism involves a metabolic switch from oxidative phosphorylation toward glycolysis allowing cells to be transiently independent of oxygen supply. Here we show that GC7 decreases protein expression of the renal GLUT1 glucose transporter leading to a decrease in transcellular glucose flux. At the same time, GC7 modifies the native energy source of the proximal cells from glutamine toward glucose use. Thus, GC7 acutely and reversibly reprogrammes function and metabolism of kidney cells to make glucose its single substrate, and thus allowing cells to be oxygen independent through anaerobic glycolysis. The physiological consequences are an increase in the renal excretion of glucose and lactate reflecting a decrease in glucose reabsorption and an increased glycolysis. Such a reversible reprogramming of glucose handling and oxygen dependence of kidney cells by GC7 represents a pharmacological opportunity in ischaemic as well as hyperglycaemia-associated pathologies from renal origin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Université Côte d’Azur, CNRS, LP2M, Nice, France (GRID:grid.463981.1)
2 CHU Nice, Hôpital Pasteur 2, Service de Réanimation Polyvalente et Service de Réanimation des Urgences Vitales, Nice, France (GRID:grid.410528.a) (ISNI:0000 0001 2322 4179)
3 Université Côte d’Azur, CNRS, LP2M, Nice, France (GRID:grid.463981.1); Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
4 Université Côte d’Azur, INSERM, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402)
5 Université Côte d’Azur, CNRS, INSERM, IRCAN, Nice, France (GRID:grid.463830.a)
6 Université de Poitiers, INSERM, IRTOMIT, CHU de Poitiers, La Milétrie, Poitiers, France (GRID:grid.463830.a)
7 CHU Poitiers, INSERM, IRTOMIT, Poitiers, France (GRID:grid.411162.1) (ISNI:0000 0000 9336 4276)
8 Université Côte d’Azur, CNRS, IPMC, Valbonne, France (GRID:grid.429194.3) (ISNI:0000 0004 0638 0649)